TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03373409
Drug: Albuterol DPI 180mcg
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
Study: NCT03373409
Drug: Albuterol HFA MDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
Study: NCT04040959
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
Study: NCT03232905
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06651600 will be administered as tablet
Study: NCT02056574
Drug: NA-1
Normalized name: Na-1
DrugBank: Nerinetide (DB12595)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01901146
Drug: ABP 980
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Study: NCT01901146
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
Study: NCT01901146
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
Study: NCT00127569
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01566474
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
Study: NCT04563507
Drug: Letrozole 2.5Mg Tab
Normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.
Study: NCT04563507
Drug: Palbociclib 125mg
Normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
Study: NCT01706679
Drug: ATX-101 (10 mg/ml)
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03151967
Drug: Lactobacillus crispatus CTV-05
Normalized name: LACTOBACILLUS CRISPATUS
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal applicator with medium containing drug
Study: NCT01706679
Drug: ATX-101 (20 mg/ml)
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01706679
Drug: Moxifloxacin (400 mg)
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00293475
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IA
Study: NCT00293475
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IA
Study: NCT04574076
Drug: Turoctocog alfa pegol (N8-GP)
Normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available N8-GP for prophylaxis and treatment of bleeding episodes according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available N8-GP has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT00293475
Drug: Sodium Thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02010970
Drug: Group 1 Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: itraconazole capsule
Study: NCT02010970
Drug: Group 2 Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem ER tablet
Study: NCT02010970
Drug: Group 3 Midazolam
Normalized name: midazolam 14.3 MG/ML
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam syrup
Study: NCT03765918
Drug: Cisplatin 100 mg/m^2
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
Study: NCT00546832
Drug: TDS-943 (topical diclofenac sodium 4% spray)
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02737436
Drug: Intranasal Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
Study: NCT00731432
Drug: Transmucosal Herbal Periodontal Patch (THPP)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch applied to oral gingiva
Study: NCT04516564
Drug: AK119
Normalized name: AK119
DrugBank: AK119 (DB16423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AK119 is administered via intravenous infusion to healthy subjects
Study: NCT00256100
Drug: Fondaparinux Sodium
Normalized name: Fondaparinux Sodium
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
Study: NCT01589029
Drug: CANAKINUMAB (ILARIS®)
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous injection every 8 weeks
Study: NCT01854073
Drug: Hyoscine butyl bromide
Normalized name: Butyl Alcohol
DrugBank: Butyl alcohol (DB02145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01140620
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
Study: NCT01140620
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: risperidone (2 mg) capsule. One dosing of 2 mg.
Study: NCT01140620
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline infusion. Duration approximately 3 hours
Study: NCT01140620
Drug: placebo risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: placebo capsule to match risperidone 2 mg capsule
Study: NCT02337426
Drug: Dimethyl Fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02337426
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03983018
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion
Study: NCT04439266
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01410435
Drug: Monofer
Normalized name: Monofer
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion according to current HB level
Study: NCT00564785
Drug: Synera(TM)
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synera(TM) patch applied 20 minutes prior to epidural
Study: NCT03166163
Drug: Azadirachta indica
Normalized name: Azadirachta indica leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
Study: NCT03166163
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
Study: NCT02150499
Drug: levalbuterol tartrate HFA inhalation aerosol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02768220
Drug: empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
Study: NCT02768220
Drug: linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
Study: NCT03131908
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
Study: NCT02169531
Drug: ex vivo Activated Immune Cells
Normalized name: Ex-vivo expanded placental adherent stromal cells
DrugBank: PLX-R18 (DB17989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
Study: NCT01038882
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of \>2 min to maintain conscious sedation
Study: NCT02050802
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02050802
Drug: Macitentan 10 mg
Normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02050802
Drug: Macitentan 30 mg
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03456726
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat will be provided as a 200 mg oral tablet.
Study: NCT01914822
Drug: methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01914822
Drug: Sugar pill (placebo)
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00611741
Drug: furosemide, Na supplements
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
Study: NCT01314911
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
Study: NCT00306202
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT).
Study: NCT00306202
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose Level 2 of 80 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.
Study: NCT00306202
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m\^2; Escalated/Dose level 2 of 80 mg/m\^2, Escalated/Dose level 3 of 100 mg/m\^2, and Escalated/Dose level 4 of 120 mg/m\^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment \> 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT.
Study: NCT04213573
Drug: silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 38% silver diamine fluoride liquid will be applied with a brush
Study: NCT00600496
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00600496
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily oral dose
Study: NCT00600496
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT00600496
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intravenous infusion
Study: NCT00163423
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00467389
Drug: Donepezil, 5 mg daily
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
Study: NCT00908063
Drug: Oxycyte
Normalized name: Oxycyte
DrugBank: Perfluoro tert-butylcyclohexane (DB12477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
Study: NCT04060888
Drug: Ustekinumab (approximately 6 mg/kg)
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
Study: NCT04060888
Drug: Ustekinumab 90 milligram (mg)
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 90 mg ustekinumab via SC route.
Study: NCT01672814
Drug: riboflavin ophthalmic solution
Normalized name: riboflavin 5'-phosphate Ophthalmic Product
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin every 2 minutes for 20 minutes
Study: NCT00045201
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00045201
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00700310
Drug: perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study: NCT00700310
Drug: perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study: NCT00700310
Drug: perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
Study: NCT00479895
Drug: Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)
Normalized name: Hemoglobin-based oxygen carrier 201 is purified, glutaraldehyde-polymerized, bovine hemoglobin, mw 250000
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-oxygenated HBOC-201
Study: NCT00400946
Drug: asparaginase
Normalized name: Asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00400946
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00400946
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00400946
Drug: dexrazoxane hydrochloride
Normalized name: Dexrazoxane Hydrochloride
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01814501
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diluted with 5% dextrose (D5W) to a total volume of 500 mL and infused intravenously over 90 minutes. Nothing else should be added to the bag. Patients will be given a dose of 180 mg/M2 by intravenous infusion.
Study: NCT00399490
Drug: RN624 (PF-04383119)
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg/kg
Study: NCT01764126
Drug: Pneumococcal protein vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study: NCT01764126
Drug: Pneumococcal protein vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study: NCT01764126
Drug: Pneumococcal protein vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study: NCT01764126
Drug: Pneumococcal protein vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
Study: NCT01764126
Drug: Pneumococcal protein vaccine
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
Study: NCT02279823
Drug: Minoxidil Solution 5%
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved marketed product
Study: NCT04042558
Drug: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
Study: NCT04042558
Drug: Carboplatin + Pemetrexed + Atezolizumab
Normalized name: Atezolizumab
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Carboplatin + Pemetrexed + Atezolizumab
Study: NCT00309868
Drug: neseritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00400946
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV